{
    "root": "e268a1a4-8598-4baa-9ff9-62ad5cab5968",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dabigatran Etexilate",
    "value": "20241031",
    "ingredients": [
        {
            "name": "DABIGATRAN ETEXILATE MESYLATE",
            "code": "SC7NUW5IIT"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 )",
    "contraindications": "• Non-valvular Atrial Fibrillation in Adult Patients: o For patients with CrCl > 30 mL/min: 150 mg orally, twice daily ( 2.2 ) o For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily ( 2.2 ) • Treatment of DVT and PE in Adult Patients: o For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation ( 2.2 ) • Reduction in the Risk of Recurrence of DVT and PE in Adult Patients : o For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after previous treatment ( 2.2 ) • Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients : o For patients with CrCl > 30 mL/min: 110 mg orally first day, then 220 mg once daily ( 2.2 ) • Treatment of Pediatric VTE: o For pediatric patients: weight-based dosage, twice daily after at least 5 days of parenteral anticoagulant ( 2.3 ) • Reduction in the Risk of Recurrence of Pediatric VTE: o For pediatric patients: weight-based dosage, twice daily after previous treatment ( 2.3 ) • Dabigatran etexilate capsules are NOT substitutable on a milligram-to-milligram basis with other dabigatran etexilate dosage forms • Review recommendations for converting to or from other oral or parenteral anticoagulants ( 2.6 , 2.7 ) • Temporarily discontinue dabigatran etexilate capsules before invasive or surgical procedures when possible, then restart promptly ( 2.8 )",
    "warningsAndPrecautions": "Dabigatran Etexilate Capsules are available containing 86.48 mg or 172.95 mg of dabigatran etexilate mesylate equivalent to 75 mg or 150 mg of dabigatran etexilate, respectively.\n                  The 75 mg capsules are hard-shell hypromellose capsules with a white opaque cap and a white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over DE 75 in black ink on both the cap and body. They are available as follows:\n                  NDC 0378-0265-93bottles of 30 capsules\n                  NDC 0378-0265-91bottles of 60 capsules\n                  The 150 mg capsules are hard-shell hypromellose capsules with a light purple opaque cap and a white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over DE 150 in black ink on both the cap and body. They are available as follows:\n                  NDC 0378-0266-93bottles of 30 capsules\n                  NDC 0378-0266-91bottles of 60 capsules\n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Once opened, the product must be used within 4 months. Keep the bottle tightly closed. Store in the original package to protect from moisture.\n                  \n                     PHARMACIST: Dispense a Medication Guide with each prescription.",
    "adverseReactions": "Dabigatran etexilate capsules are contraindicated in patients with: \n                  \n                     \n                        •Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]\n                     \n                     \n                        •History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions (6.1)]\n                     \n                     \n                        •Mechanical prosthetic heart valve [see Warnings and Precautions (5.4)]"
}